Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators

Manuscript Number: 

15-0818R1

Author(s): 
Kiyoshi Fujita, Nakao Iwata, Taro Kishi, Shinji Matsunaga, Ichiro Yasue

Disclosures

Kiyoshi Fujita

  • Lecture Fees:
    Fujita has received speaker’s honoraria from Eli Lilly, Mochida, GlaxoSmithKline, Janssen, Yoshitomi, and Otsuka.

Nakao Iwata

  • Lecture Fees:
    Iwata has received speaker’s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer.
    Grants
    • Agency: 
      Otuka
      Dates: 
      2015
    • Agency: 
      GlaxoSmithKline
      Dates: 
      2015

Taro Kishi

  • Lecture Fees:
    Kishi has received speaker’s honoraria from Abbott, Astellas, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Yoshitomi, Otsuka, Meiji, Shionogi, Janssen, Novartis, Tanabe-Mitsubishi, and Pfizer.

Shinji Matsunaga

  • Lecture Fees:
    Matsunaga has received speaker’s honoraria from Eisai, Janssen, Novartis, Daiichi Sankyo, Ono, Eli Lilly, Takeda, and Otsuka.

Ichiro Yasue

  • Lecture Fees:
    Yasue has received speaker’s honoraria from Otsuka, Eli Lilly, Janssen, Novartis, and Eisai.